3-methoxycarbonylamino-1-methyl-2-indolinone | 110599-56-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-methoxycarbonylamino-1-methyl-2-indolinone
• 英文别名: (1-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl)-carbamic acid methyl ester；methyl N-(1-methyl-2-oxo-3H-indol-3-yl)carbamate
• CAS: 110599-56-9
• 化学式: C₁₁H₁₂N₂O₃
• 分子量: 220.228
• InChiKey: YKLFWXUYFOXVAL-UHFFFAOYSA-N

物化性质

• 熔点：
  158-159 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• 沸点：
  446.5±45.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1R,2S,5R)-menthol bromoacetate 、 3-methoxycarbonylamino-1-methyl-2-indolinone 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 生成 ((R)-3-methoxycarbonylamino-1-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl)acetic acid (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl ester 、 ((S)-3-methoxycarbonylamino-1-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl)acetic acid (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl ester
  参考文献：
  名称：

  羟吲哚烯醇酸酯的高立体选择性烷基化反应有效合成新型胃泌素受体拮抗剂AG-041R

  摘要：

  开发了有效的不对称合成有效的胃泌素/ CCK-B受体拮抗剂AG-041R的有效方法。使用1-薄荷醇作为手性助剂，通过用溴乙酸酯对羟吲哚烯醇酸酯的不对称烷基化来建立核心羟吲哚立体化学。羟吲哚烯醇化物的关键烷基化反应生成具有高非对映选择性的四取代手性中间体。详细描述了立体选择性烷基化反应。

  DOI：

  10.1021/jo061541v
• 作为产物：
  描述：

  N-methylbismethoxycarbonylaminoacetanilide 在 甲烷磺酸 作用下， 反应 48.0h， 以63%的产率得到3-methoxycarbonylamino-1-methyl-2-indolinone
  参考文献：
  名称：

  芳族化合物的分子内与分子间酰胺烷基化

  摘要：

  研究了三种芳香族化合物的分子内酰胺基烷基化反应，分别是两种内三角键和一种外键（I，II，III），它们导致了吲哚酮，N-酰基异喹啉，异喹诺酮和苯并ze庚酮衍生物。在存在外部芳族亲核试剂的情况下，观察到竞争性的分子间酰胺烷基化反应（1→2,13→14）。讨论了三种环化的机理和合成的局限性。

  DOI：

  10.1016/s0040-4020(01)89976-2

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020173504A1

  公开（公告）日：2002-11-21

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及抑制&bgr;-淀粉样肽的释放和/或合成的化合物，因此具有治疗阿尔茨海默病的效用。还公开了包含抑制&bgr;-淀粉样肽释放和/或合成的化合物的药物组合物，以及使用这种药物组合物预防和治疗阿尔茨海默病的方法。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20040106598A1

  公开（公告）日：2004-06-03

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions that include a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及抑制β-淀粉样肽释放和/或合成的化合物，因此在治疗阿尔茨海默病方面具有用途。还公开了包括抑制β-淀粉样肽释放和/或合成的化合物的药物组合物，以及使用这种药物组合物预防和治疗阿尔茨海默病的方法。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-Amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020111343A1

  公开（公告）日：2002-08-15

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及一种抑制β-淀粉样肽释放和/或合成的化合物，因此具有治疗阿尔茨海默病的效用。本发明还涉及包含抑制β-淀粉样肽释放和/或合成的化合物的制药组合物，以及使用这种制药组合物预防和治疗阿尔茨海默病的方法。
• Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20030130188A1

  公开（公告）日：2003-07-10

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明揭示了一些化合物，可以抑制&bgr;-淀粉样肽的释放和/或合成，因此在治疗阿尔茨海默病方面具有实用性。本发明还揭示了包含抑制&bgr;-淀粉样肽释放和/或合成的化合物的制药组合物，以及使用这些制药组合物预防和治疗阿尔茨海默病的方法。